Goldman Sachs made significant rating changes across its U.S. biopharma coverage on Tuesday, upgrading the likes of Eli Lilly ...

Upgrading J&J (NYSE:JNJ) to Buy from Neutral ... However, Haider downgraded AbbVie (NYSE:ABBV) to Neutral from Buy, and trimmed its 12-month price target to $194 from $212 per share, arguing ...

Goldman updates coverage across major U.S. drugmakers, citing exclusivity risks, pricing power, and pipeline outlooks ...

AbbVie’s Skyrizi and Rinvoq were practically unshakeable atop the monthly TV drug ad spending rankings, ultimately leading ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization to RINVOQ� (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in ...

The 90-day pause in tariffs temporally slowed the bloodbath with stocks it is too soon to consider a recovery rally.  Several ...

and AbbVie has just claimed important territory ahead of its main rivals while it awaits for the results of an ongoing phase 3 ulcerative colitis trial. J&J has phase 2 results in hand with ...

It’s been very successful, following pharmacyclics, which is now AbbVie J and J. There are four companies about to be six, all targeting the BTK kinase, which all down regulate NF kappa b. There’s ...